UroGen Pharma Sees Unusually High Options Volume (NASDAQ:URGN)

UroGen Pharma Ltd. (NASDAQ:URGN - Get Free Report) was the recipient of unusually large options trading activity on Friday. Stock investors bought 5,604 call options on the company. This is an increase of approximately 222% compared to the typical daily volume of 1,741 call options.

Analyst Ratings Changes

A number of research analysts have issued reports on the stock. The Goldman Sachs Group cut their target price on shares of UroGen Pharma from $16.00 to $3.00 and set a "neutral" rating on the stock in a research report on Thursday, May 22nd. Guggenheim lowered their target price on UroGen Pharma from $40.00 to $15.00 and set a "buy" rating for the company in a research note on Friday, May 23rd. LADENBURG THALM/SH SH began coverage on UroGen Pharma in a research note on Wednesday, February 19th. They set a "buy" rating and a $31.00 target price for the company. Oppenheimer decreased their price target on shares of UroGen Pharma from $36.00 to $10.00 and set an "outperform" rating for the company in a research note on Tuesday. Finally, D. Boral Capital reissued a "buy" rating and issued a $25.00 target price on shares of UroGen Pharma in a research note on Thursday, May 8th. Two research analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $23.14.

UroGen Pharma Stock Performance

UroGen Pharma stock traded up $2.23 during mid-day trading on Friday, hitting $7.37. 20,701,335 shares of the company's stock traded hands, compared to its average volume of 824,987. UroGen Pharma has a fifty-two week low of $3.42 and a fifty-two week high of $20.70. The company has a debt-to-equity ratio of 4.77, a current ratio of 9.00 and a quick ratio of 8.77. The stock has a market cap of $339.81 million, a price-to-earnings ratio of -2.34 and a beta of 0.40. The firm has a 50 day simple moving average of $8.68 and a two-hundred day simple moving average of $10.18.

UroGen Pharma (NASDAQ:URGN - Get Free Report) last posted its earnings results on Monday, May 12th. The company reported ($0.92) earnings per share for the quarter, missing analysts' consensus estimates of ($0.83) by ($0.09). The firm had revenue of $20.25 million during the quarter, compared to the consensus estimate of $22.71 million. On average, research analysts expect that UroGen Pharma will post -3.12 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the stock. CWM LLC raised its stake in UroGen Pharma by 6,047.1% in the first quarter. CWM LLC now owns 5,225 shares of the company's stock valued at $58,000 after purchasing an additional 5,140 shares in the last quarter. KLP Kapitalforvaltning AS acquired a new position in UroGen Pharma in the fourth quarter valued at about $59,000. Lazard Asset Management LLC bought a new position in UroGen Pharma in the fourth quarter valued at about $67,000. GAMMA Investing LLC grew its position in UroGen Pharma by 6,908.4% in the first quarter. GAMMA Investing LLC now owns 7,499 shares of the company's stock valued at $83,000 after acquiring an additional 7,392 shares during the last quarter. Finally, Aquatic Capital Management LLC bought a new position in UroGen Pharma in the fourth quarter valued at about $101,000. Institutional investors and hedge funds own 91.29% of the company's stock.

UroGen Pharma Company Profile

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.